Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy

ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline project: a unique and innovative co-development partnership with the NPHP1 Family Foundation to...